Dafin Fior Muresanu
Dafin Fior Muresanu
Verified email at umfcluj.ro
TitleCited byYear
Blood-brain barrier alterations in ageing and dementia
BO Popescu, EC Toescu, LM Popescu, O Bajenaru, DF Muresanu, ...
Journal of the neurological sciences 283 (1-2), 99-106, 2009
A 24‐week, double‐blind, placebo‐controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
XA Alvarez, R Cacabelos, M Laredo, V Couceiro, C Sampedro, M Varela, ...
European journal of neurology 13 (1), 43-54, 2006
Mild traumatic brain injury
PE Vos, Y Alekseenko, L Battistin, E Ehler, F Gerstenbrand, DF Muresanu, ...
European journal of neurology 19 (2), 191-198, 2012
Post-stroke dementia–a comprehensive review
MD Mijajlović, A Pavlović, M Brainin, WD Heiss, TJ Quinn, ...
BMC medicine 15 (1), 1-12, 2017
Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action
F Machicao, DF Muresanu, H Hundsberger, M Pflüger, A Guekht
Journal of the neurological sciences 322 (1-2), 222-227, 2012
Cerebrolysin and Recovery After Stroke (CARS) A randomized, placebo-controlled, double-blind, multicenter trial
DF Muresanu, WD Heiss, V Hoemberg, O Bajenaru, CD Popescu, ...
Stroke 47 (1), 151-159, 2016
A review of published reports on neuroprotection in spinal cord injury
G Onose, A Anghelescu, DF Muresanu, L Padure, MA Haras, ...
Spinal Cord 47 (10), 716-726, 2009
Chronic treatment with nanoparticles exacerbate hyperthermia induced blood-brain barrier breakdown, cognitive dysfunction and brain pathology in the rat. Neuroprotective …
HS Sharma, SF Ali, ZR Tian, SM Hussain, JJ Schlager, PO Sjöquist, ...
Journal of nanoscience and nanotechnology 9 (8), 5073-5090, 2009
Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals
P Kumaran Menon, D Fior Muresanu, A Sharma, H Mossler, ...
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2012
Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle
A Popa-Wagner, AM Buga, B Popescu, D Muresanu
Journal of neural transmission 122 (1), 47-54, 2015
Neuroregeneration in neurodegenerative disorders
AM Enciu, MI Nicolescu, CG Manole, DF Mureşanu, LM Popescu, ...
BMC neurology 11 (1), 75, 2011
Neuroprotection and neuroplasticity–a holistic approach and future perspectives
DF Muresanu
Journal of the neurological sciences 257 (1-2), 38-43, 2007
Cocaine-induced breakdown of the blood–brain barrier and neurotoxicity
HS Sharma, D Muresanu, A Sharma, R Patnaik
International review of neurobiology 88, 297-334, 2009
Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin®
DF Muresanu, M Rainer, H Moessler
Ageing and Dementia Current and Future Concepts, 277-285, 2002
A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration
DF Muresanu, XA Alvarez, H Moessler, M Buia, A Stan, D Pintea, ...
Journal of the neurological sciences 267 (1-2), 112-119, 2008
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease
K Gadhave, N Bolshette, A Ahire, R Pardeshi, K Thakur, C Trandafir, ...
Journal of cellular and molecular medicine 20 (7), 1392-1407, 2016
Size-and age-dependent neurotoxicity of engineered metal nanoparticles in rats
A Sharma, DF Muresanu, R Patnaik, HS Sharma
Molecular neurobiology 48 (2), 386-396, 2013
Neurotrophic factors
DF Muresanu
Bucuresti: Libripress 196, 2003
Towards a roadmap in brain protection and recovery
DF Muresanu, A Buzoianu, SI Florian, T von Wild
Journal of cellular and molecular medicine 16 (12), 2861-2871, 2012
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 ‐1639 G>A polymorphisms in a population from South‐Eastern Europe
AD Buzoianu, AP Trifa, DF Mureşanu, S Crişan
Journal of cellular and molecular medicine 16 (12), 2919-2924, 2012
The system can't perform the operation now. Try again later.
Articles 1–20